$646 Million is the total value of NEXTHERA CAPITAL LP's 45 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 118.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMMU | Buy | Immunomedics Inc | $31,460,000 | +99.1% | 1,329,104 | +22.9% | 4.87% | +87.2% |
| EXEL | New | Exelixis Inc | $30,593,000 | – | 1,421,600 | +100.0% | 4.74% | – |
| BMRN | Buy | BioMarin Pharmaceutical Inccall | $28,260,000 | +223.7% | 300,000 | +178.6% | 4.38% | +204.2% |
| DOVA | Buy | Dova Pharmaceuticals Inc | $24,545,000 | +59.3% | 820,348 | +44.4% | 3.80% | +49.7% |
| TSRO | New | TESARO Inc | $19,278,000 | – | 433,500 | +100.0% | 2.98% | – |
| AZN | Buy | AstraZeneca PLCsponsored adr | $18,267,000 | +7.9% | 520,279 | +7.5% | 2.83% | +1.5% |
| GBT | Buy | Global Blood Therapeutics Inc | $18,265,000 | +20.0% | 404,092 | +28.2% | 2.83% | +12.8% |
| PCRX | Buy | Pacira Pharmaceuticals Inc/DE | $18,157,000 | +21.8% | 566,508 | +18.4% | 2.81% | +14.5% |
| ALXN | New | Alexion Pharmaceuticals Inc | $16,465,000 | – | 132,623 | +100.0% | 2.55% | – |
| MYL | Buy | Mylan NV | $15,613,000 | +45.3% | 432,009 | +65.5% | 2.42% | +36.6% |
| CLLS | Buy | Cellectis SAsponsored ads | $15,509,000 | +47.9% | 548,212 | +64.7% | 2.40% | +39.0% |
| SGMO | Buy | Sangamo Therapeutics Inc | $15,150,000 | +1.4% | 1,066,914 | +35.7% | 2.35% | -4.6% |
| SAGE | Buy | Sage Therapeutics Inc | $12,378,000 | -1.8% | 79,080 | +1.1% | 1.92% | -7.7% |
| ESPR | New | Esperion Therapeutics Inc | $11,259,000 | – | 287,300 | +100.0% | 1.74% | – |
| ABEO | Buy | Abeona Therapeutics Inc | $10,029,000 | +89.2% | 626,804 | +69.6% | 1.55% | +77.9% |
| BOLD | New | Audentes Therapeutics Inc | $9,228,000 | – | 241,500 | +100.0% | 1.43% | – |
| CBIO | Buy | Catalyst Biosciences Inc | $9,183,000 | -33.9% | 786,865 | +46.1% | 1.42% | -37.8% |
| STML | Buy | Stemline Therapeutics Inc | $8,980,000 | +12.1% | 559,517 | +6.9% | 1.39% | +5.4% |
| CARA | Buy | Cara Therapeutics Inc | $8,346,000 | +92.0% | 435,800 | +24.1% | 1.29% | +80.4% |
| ECYT | New | Endocyte Inc | $8,225,000 | – | 596,000 | +100.0% | 1.27% | – |
| KURA | Buy | Kura Oncology Inc | $6,943,000 | +5.2% | 381,459 | +8.4% | 1.08% | -1.1% |
| DCPH | New | Deciphera Pharmaceuticals Inc | $5,108,000 | – | 129,800 | +100.0% | 0.79% | – |
| ACOR | New | Acorda Therapeutics Inc | $4,259,000 | – | 148,380 | +100.0% | 0.66% | – |
| ONCS | Buy | OncoSec Medical Inc | $3,608,000 | -7.0% | 2,614,297 | +26.6% | 0.56% | -12.5% |
| NEOS | New | Neos Therapeutics Inc | $2,369,000 | – | 378,961 | +100.0% | 0.37% | – |
| MGTA | New | Magenta Therapeutics Inc | $2,025,000 | – | 150,000 | +100.0% | 0.31% | – |
| ARPO | New | Aerpio Pharmaceuticals Inc | $1,240,000 | – | 298,873 | +100.0% | 0.19% | – |
| VSAR | New | Versartis Inc | $1,013,000 | – | 500,000 | +100.0% | 0.16% | – |
| TGTX | New | TG Therapeutics Inc | $949,000 | – | 72,200 | +100.0% | 0.15% | – |
| MTEM | New | Molecular Templates Inc | $902,000 | – | 172,384 | +100.0% | 0.14% | – |
| CRBP | New | Corbus Pharmaceuticals Holding | $678,000 | – | 134,280 | +100.0% | 0.10% | – |
| KNSA | New | Kiniksa Pharmaceuticals Ltd | $680,000 | – | 39,180 | +100.0% | 0.10% | – |
| TGTX | New | TG Therapeutics Inccall | $658,000 | – | 50,000 | +100.0% | 0.10% | – |
| MDWD | New | MediWound Ltd | $308,000 | – | 44,576 | +100.0% | 0.05% | – |
| AVRO | New | Avrobio Inc | $286,000 | – | 10,000 | +100.0% | 0.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Insmed Inc | 13 | Q2 2019 | 10.0% |
| Global Blood Therapeutics Inc | 11 | Q2 2019 | 6.2% |
| Shire PLC | 9 | Q1 2018 | 13.6% |
| Immunomedics Inc | 9 | Q2 2019 | 7.8% |
| Allergan PLC | 8 | Q2 2019 | 7.6% |
| FibroGen Inc | 8 | Q3 2018 | 3.0% |
| Abeona Therapeutics Inc | 8 | Q3 2018 | 2.1% |
| Pfizer Inc | 7 | Q2 2017 | 19.1% |
| Seattle Genetics Inc | 7 | Q2 2018 | 5.7% |
| Mylan NV | 7 | Q2 2019 | 6.5% |
View NEXTHERA CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CATALYST BIOSCIENCES, INC. | February 14, 2019 | 376,010 | 3.1% |
| CHIASMA, INC | February 14, 2019 | 1,066,439 | 4.4% |
| ONCOSEC MEDICAL IncSold out | February 14, 2019 | 0 | 0.0% |
| Zosano Pharma Corp | April 05, 2018 | 700,000 | 5.9% |
| VistaGen Therapeutics, Inc. | May 24, 2016 | 138,132 | 1.8% |
View NEXTHERA CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G | 2018-11-26 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| SC 13G | 2018-06-11 |
View NEXTHERA CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.